VRX - Valeant Pharmaceuticals Intern
This page shows which of the focused investors we track hold VRX and how their positions changed, so you can see how much conviction the group has in the stock.
In Q1 2016 it was held by 9 managers with an aggregate reported value of $2.16B, which is 0.30% of the combined portfolio.
As of Q1 2016, 9 tracked institutional managers held VRX (Valeant Pharmaceuticals Intern) with an aggregate reported value of $2.16B — 0.30% of the combined AlphaBaseline portfolio.
Get email alerts when a tracked manager trades VRX — sign in or create a free account.
- Source
- Curated SEC 13F filings
- Period
- Q1 2016
- Ticker
- VRX
13F data is delayed and excludes shorts/non-13F assets.
Holders
| 1 | Ruane Cunniff LP - Ruane Cunniff LP | 6.19% | Reduce -14.3% | 30,308,449 | $797.11M |
| 2 | Bill Ackman - Pershing Square Capital Management | 6.41% | Add +30.1% | 21,591,122 | $567.85M |
| 3 | ValueAct Capital - ValueAct Capital | 3.94% | - | 14,994,261 | $394.35M |
| 4 | Christopher Davis - Davis Advisors | 0.84% | Add +91.3% | 7,240,337 | $190.42M |
| 5 | First Eagle - First Eagle Investment Management | 0.16% | Reduce -8.3% | 1,507,302 | $61.43M |
| 6 | Glenn Greenberg - Brave Warrior Advisors | 2.61% | Reduce -67.5% | 2,034,281 | $53.5M |
| 7 | Bill Miller - Miller Value Partners | 1.60% | New | 1,580,950 | $41.58M |
| 8 | Francis Chou - Chou Associates | 5.65% | New | 976,843 | $25.73M |
| 9 | David Tepper - Appaloosa Management | 0.44% | New | 945,000 | $24.85M |
Loading holder history for VRX…